Olympus Corp. is acquiring Quest Photonic Devices BV, a developer of multispectral imaging solutions serving medical markets. The deal is worth up to approximately $60.7 million (€50 million). Olympus, in a press release, said the planned acquisition enhances its surgical endoscopy market presence. Quest offers advanced fluorescence imaging systems for the medical field, enabling more surgical endoscopy capabilities compared to conventional imaging technologies. Fluorescence imaging refers to special light imaging technologies that use the properties of fluorescent dyes directed to specific anatomical structures. When targeted dyes combine with specific light wavelengths, lesions that are nearly invisible under normal white light become visible.